NextCure shareholders elect three Class III directors and ratify Ernst & Young auditor

NextCure, Inc.

Elected David Kabakoff (11,548,824 for, 1,187,004 against), Michael Richman (11,609,302 for, 1,124,238 against), and Stephen W. Webster (11,530,304 for, 1,202,184 against) as Class III directors.
Ratified Ernst & Young as independent auditor for FY2022 with 17,631,748 for, 53,399 against, 79,774 abstain.
Broker non-votes on director election totaled 4,783,701, with no broker non-votes on ratification.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.